Nektar Therapeutics management will attend the UBS Global Biopharma Conference on November 17 and the Jefferies Global Healthcare Conference on November 18 in London to conduct fireside chats and investor meetings.
Nektar announced only that management will attend the UBS Global Biopharma Conference (Nov 17, 2026) and Jefferies Global Healthcare Conference (Nov 18, 2026) in London for fireside chats and 1x1 meetings. No financial figures, trial data, or guidance are disclosed, so there is no material new information to move the stock.
Nektar Therapeutics announced that management will participate in two investor conferences in London this November. The company will hold fireside chats and one-on-one meetings at the UBS Global Biopharma Conference on November 17 and the Jefferies Global Healthcare Conference on November 18, 2026.
No. It only announces management's participation in two investor conferences on November 17 and 18, 2026, with webcasts available on the company's website; it contains no new financial or pipeline results.